These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6548212)

  • 21. Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.
    Twentyman P; Workman P
    Br J Cancer; 1982 Mar; 45(3):447-55. PubMed ID: 7073938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
    Brown JM; Hirst DG
    Br J Cancer; 1982 May; 45(5):700-8. PubMed ID: 7082556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.
    McNally NJ; Hinchliffe M; de Ronde J
    Br J Cancer; 1983 Aug; 48(2):271-8. PubMed ID: 6882665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds.
    Sheldon PW; Batten EL; Adams GE
    Br J Cancer; 1982 Oct; 46(4):525-31. PubMed ID: 7138761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
    Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
    Hinchliffe M; McNally NJ
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S; Stratford IJ; Fielden EM; Adams GE; Leopold W; Elliott W; Suto M; Sebolt-Leopold J
    Int J Radiat Oncol Biol Phys; 1992; 22(3):545-8. PubMed ID: 1735694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S; Stratford IJ; Bowler J; Nolan J; Wright EG; Lorimore SA; Adams GE
    Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiation of combination chemotherapy by nitroheterocyclics.
    Siemann DW; Allalunis-Turner MJ
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):129-34. PubMed ID: 3391809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing the chemosensitization of melphalan by misonidazole.
    Randhawa VS; Stewart FA; Denekamp J; Stratford MR
    Br J Cancer; 1985 Feb; 51(2):219-28. PubMed ID: 3966979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut.
    Mulcahy RT; Siemann DW; Sutherland RM
    Br J Cancer; 1982 Jun; 45(6):835-42. PubMed ID: 6212075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP; Gulyas S; Whitmore GF
    Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro.
    Mulcahy RT; Dembs N
    Cancer Res; 1983 Aug; 43(8):3539-43. PubMed ID: 6861127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
    Siemann DW
    Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
    Workman P; Twentyman PR
    Br J Cancer; 1982 Aug; 46(2):249-59. PubMed ID: 7150475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
    Twentyman PR
    Br J Cancer; 1981 Jun; 43(6):745-55. PubMed ID: 6264941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of radiosensitizer pretreatment on the response of the RIF-1 mouse sarcoma to cytotoxic drugs.
    Twentyman PR; Workman P
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):611-3. PubMed ID: 7107382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M; Workman P
    Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
    Mulcahy RT; Siemann DW; Sutherland RM
    Br J Cancer; 1981 Jan; 43(1):93-9. PubMed ID: 7459244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872.
    Siemann DW
    Radiother Oncol; 1995 Jan; 34(1):47-53. PubMed ID: 7792398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.